Five years post-turducken: The Tipline for 18 June 2018
Yesterday was the fifth anniversary of the Supreme Court’s ruling in Federal Trade Commission v Actavis, holding that reverse-payment settlements by pharmaceutical patent-holders can – but do not necessarily – violate US antitrust law. Check out the Cases section of this morning’s Tipline for the latest in the litigation, which is still going on in federal district court. We also have news from deputy assistant attorney general Don Kempf; the FTC’s challenge to Tronox/Cristal; and an unusual jury conclusion that antitrust defendants conspired but should not be liable for damages.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10